Leica Biosystems to Acquire Devicor Medical Products, Inc.

PR58408

BUFFALO GROVE, Illinois, Oct. 28 /PRN=KYODO JBN/ --

Leica Biosystems, a global leader in anatomic pathology laboratory solutions

and instruments, announced today that it has entered into a definitive

agreement to acquire Devicor Medical Products, Inc.

Devicor is a global market leader in breast biopsy instruments and consumables,

with annual revenues of approximately $170 million. Devicor, headquartered in

Cincinnati, Ohio, has more than 550 employees and sells products in more than

50 countries around the world. It is committed to advancing technology to help

clinicians accurately diagnose breast disease, such as breast cancer, through

minimally invasive procedures.

"Leica Biosystems' products and solutions address the key steps across the

anatomic pathology workflow. The addition of Devicor's market leading breast

biopsy products, especially Mammotome, allows us to further integrate that

workflow from the source, starting with the patient and the biopsy sample,"

said Matthias Weber, MD, President of Leica Biosystems. "This acquisition

supports our mission of advancing cancer diagnostics to improve lives by adding

products that will have direct benefits for the patients and the clinicians who

care for them."

Among Devicor's products is the Original Mammotome Breast Biopsy System, which,

to date, has enabled more than four million women to have a minimally invasive

breast biopsy. Devicor's product portfolio also includes the Mammotome revolve,

the tether-less Mammotome elite, Neoprobe Gamma Detection System, Mammotome

MammoTest stereotactic biopsy table, as well as a comprehensive portfolio of

tissue markers used in breast disease diagnostic sampling and management.

Devicor will operate as a standalone business within Leica Biosystems and will

continue to be led by Tom Daulton, the current CEO of Devicor. "Our portfolio

of products is highly complementary with Leica's. We are excited about our

future as part of Leica. Integrating the pathology workflow will open the door

to further improve efficiency, diagnostic quality and patient outcomes," said

Daulton.

The transaction is expected to close in early 2015. The agreement is subject to

applicable regulatory approvals and other customary closing conditions. No

other financial terms and conditions have been disclosed.

About Leica Biosystems  

Leica Biosystems, part of Danaher Corporation's (NYSE:DHR) Diagnostics

platform, is a global leader in workflow solutions and automation, striving to

advance cancer diagnostics to improve patients' lives. Leica Biosystems

provides anatomic pathology laboratories and researchers a comprehensive

product range for each step in the pathology process, from sample preparation

and staining to imaging and reporting. Leica Biosystems' easy-to-use and

consistently reliable offerings help improve workflow efficiency and diagnostic

confidence. The company is represented in over 100 countries. It has

manufacturing facilities in 8 countries, sales and service organizations in 27

countries, and a network of dealers spanning the globe. The company is

headquartered in Nussloch, Germany. Visit http://www.LeicaBiosystems.com for

more information.

LEICA and the Leica logo are registered trademarks of Leica Microsystems IR

GmbH.

Devicor, Mammotome, Mammotome revolve, Mammotome elite, MammoTest, and Neoprobe

are trademarks of Devicor, Inc.

Contact:

Diane Mielnikowski

Leica Biosystems

Phone: +1-847-257-3111

Email: Diane.Mielnikowski@leicabiosystems.com

Source: Leica Biosystems